Document is current
Any future updates will be listed below
-
Authors
Su, Alan
Hong, Erin C.
Moxon, Nicole
Mellinger, Staci L.
Kelly, Tracy
Conlin, Alison K.
Topp, Zheng Zhu
Newell, Philippa
Fredrich, Nicole
Massimino, Kristen P.
Wu, Yaping
Martel, Maritza
Redmond, William L.
Aliabadi-Wahle, Shaghayegh
Sun, Zhaoyu
Imatani, James
Stanton, Sasha E.
Hanes, Douglas A.
Simanonok, Michael
Rosales, Wesley
Nielsen, Tyler J.
Page, David B.
-
Funding
Funding for this research was provided by:
Merck Sharp & Dohme LLC
Brooklyn Immunotherapeutics
- License Information
-
More Information
Article History
Received: 11 November 2025
Accepted: 24 February 2026
First Online: 17 March 2026
Competing interests
: A.C. serves in an advisory role for Seattle Genetics/Astellas, AstraZeneca, and Gilead Sciences. W.R. receives institutional research support from GlaxoSmithKline, Inhibrx, Shimadzu, and Galecto. They also hold a patent with Galectin Therapeutics. Lastly, they serve in an advisory role for Vesselon and Medicenna. S.S. receives institutional research support from IMV Inc. They also receive consulting fees from Margenza and Stanford Burnham Prebys. T.J.N. is currently employed with Oncocyte. D.B.P. receives institutional research support from Merck, Bristol-Myers Squibb, and Brooklyn Immunotherapeutics. They also receive consulting fees from AstraZeneca, D-S, Lilly, Genentech, Gilead, Merck, NGM Bio, Novartis, Pfizer, and Stemline. They also have a speaking honoraria with Novartis and Pfizer. The other authors declare no other Competing Financial or Non-Financial Interests.
